<DOC>
	<DOC>NCT01818869</DOC>
	<brief_summary>This study will investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of AZD8848 in healthy subjects.</brief_summary>
	<brief_title>To Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses AZD8848 in Healthy Subjects</brief_title>
	<detailed_description>A Phase 1, Single Centre, Double-blind, Randomised, Placebo-controlled, Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics after Administration of Multiple Ascending (MAD) Once Weekly Inhaled Doses of AZD8848 in Healthy Subjects</detailed_description>
	<criteria>Healthy male and/or female subjects aged 18 to 50 years (inclusive) with suitable veins for cannulation or repeated venipuncture Women must be of nonchildbearing potential or must have been stable on a highly effective contraceptive for at least 3 months prior to Screening and be willing to continue on the chosen contraceptive with additonal use of condom until 3 months postdose Male subjects should be willing to use barrier contraception ie, condoms, from the first day of investigational product administration until 3 months after the last administration of investigational product Have a body mass index (BMI) between 18 and 32 kg/m2 and weigh at least 50 kg and no more than 110 kg Women must have a negative pregnancy test at screening and on admission to the study centre, must have a date of last menstruation, must not be lactating or must be of nonchildbearing potential Abnormal vital signs, after 10 minutes supine rest, defined as any of the following: SBP &gt;140 mmHg, Diastolic blood pressure (DBP) &gt;90 mmHg, Heart rate &lt;40 or &gt;85 beats per minute History of asthma or allergic rhinitis Prolonged QTcF &gt;450 ms or shortened QTcF &lt;340 ms or family history of long QT syndrome History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the Investigator or history of hypersensitivity to drugs with a similar chemical structure or class as AZD8848 Any clinically significant abnormalities in clinical chemistry.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Safety,</keyword>
	<keyword>tolerability,</keyword>
	<keyword>Phase I,</keyword>
	<keyword>pharmacokinetic,</keyword>
	<keyword>pharmacodynamic,</keyword>
	<keyword>inhaled</keyword>
</DOC>